Clinical Trial Update: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/2 study of Niraparib in combination with Trastuzumab for metastatic HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Metastatic Breast Cancer, HER2 Positive Breast Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING